Selv om antallet af centralt godkendte produkter vokser betydeligt, kommer der meget få indberetninger om bivirkninger, og derfor har arbejdsgruppen hovedsagelig fokuseret på periodiske ajourføringer af kriterierne for overvågning af sikkerheden ved centralt godkendte præparater.
Although the number of centrally approved products being approved is significantly increasing, very few adverse reactions are being reported, so that the working party has focussed mainly on periodic safety updates for monitoring safety of centrally approved products.